Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EPS (Weighted Average and Diluted): 2015-2025

Historic EPS (Weighted Average and Diluted) for Coherus Oncology (CHRS) over the last 8 years, with Sep 2025 value amounting to -$0.38.

  • Coherus Oncology's EPS (Weighted Average and Diluted) rose 7.32% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.43, marking a year-over-year increase of 576.39%. This contributed to the annual value of $0.25 for FY2024, which is 109.88% up from last year.
  • Coherus Oncology's EPS (Weighted Average and Diluted) amounted to -$0.38 in Q3 2025, which was down 114.79% from $2.57 recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's EPS (Weighted Average and Diluted) registered a high of $2.57 during Q2 2025, and its lowest value of -$2.37 during Q1 2021.
  • Its 3-year average for EPS (Weighted Average and Diluted) is $0.08, with a median of -$0.41 in 2024.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first slumped by 690.00% in 2021, then spiked by 635.42% in 2025.
  • Coherus Oncology's EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.59 in 2021, then dropped by 28.81% to -$0.76 in 2022, then rose by 2.63% to -$0.74 in 2023, then surged by 333.78% to $1.73 in 2024, then grew by 7.32% to -$0.38 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.38 in Q3 2025, compared to $2.57 in Q2 2025 and -$0.49 in Q1 2025.